NDA 022187 · Janssen R and D
Intelence
Etravirine · Oral · Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
NovelAccelerated approvalPriority reviewLast checked: Nov 20, 2026Latest source record: Jul 10, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2008
Jan 18, 2008
Approved uses
5
Original approval plus efficacy supplements
Registered trials
73
20 Phase 3, 0 recruiting
FAERS reports
4,438
3,903 serious, 475 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 2, 2025.
Etravirine, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients and pediatric patients 2 years of age and older [see Microbiology (12.4) and Clinical Studies (14) ] . Etravirine is a human immunodeficiency virus type 1 (HIV-1) non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated for treatment of HIV-1 infection in treatment-experienced patients 2 years of age and older. ( 1 )
Mechanism: Etravirine is an antiretroviral drug [see Microbiology (12.4) ] .
Therapeutic areas: Infectious disease and vaccines · Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 6, 2018 Supplement 23 · Efficacy LabelLetter
- Jul 16, 2018 Supplement 24 · Efficacy · priority review LabelLetterPediatric CDTL Review
- Mar 26, 2012 Supplement 9 · Efficacy · priority review LetterLabel
- Nov 24, 2009 Supplement 1 · Efficacy Label
- Jan 18, 2008 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalLabelReviewSummary Review
3 products under this application
- INTELENCE · ETRAVIRINE 200MG · TABLET, ORAL · Prescription · TE AB
- INTELENCE · ETRAVIRINE 25MG · TABLET, ORAL · Prescription
- INTELENCE · ETRAVIRINE 100MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Etravirine" as an intervention, any sponsor and status, largest first.
- Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus RaltegravirPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT00708162 · 724 participants · Start Jul 2008 · Primary completion Dec 2010
Drug: Elvitegravir; Raltegravir and 3 more · For: HIV Infection
Sites: Phoenix, Arizona; Little Rock, Arkansas; Beverly Hills, California · 180 sites in all
- Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected PatientsPivotal-lookingCompleted
ANRS, Emerging Infectious DiseasesGovernment (non-federal)
NCT03256422 · 640 participants · Start Sep 7, 2017 · Primary completion Aug 6, 2019
Drug: Treatment discontinuation · For: HIV Infections
Sites: Pointe à Pitre, France; Fort-de-France, France; Argenteuil, France · 63 sites in all
Tibotec Pharmaceuticals, IrelandIndustry
NCT00254046 · 616 participants · Start Nov 2005 · Primary completion Feb 2007
Drug: TMC125; Placebo · For: HIV
Sites: Little Rock, Arkansas; Beverly Hills, California; Los Angeles, California · 55 sites in all
Tibotec Pharmaceuticals, IrelandIndustry
NCT00255099 · 593 participants · Start Dec 2005 · Primary completion Jan 2007
Drug: TMC125; Placebo · For: HIV
- A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral FailurePivotal-lookingCompleted
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsResearch network
NCT01641367 · 545 participants · Start Feb 22, 2013 · Primary completion Nov 23, 2016
Drug: Darunavir; Etravirine and 4 more · For: HIV-1 Infection
Sites: Porto Alegre, Brazil; Rio de Janeiro, Brazil; Port-au-Prince, Haiti · 19 sites in all
- Optimizing Treatment for Treatment-Experienced, HIV-Infected PeoplePivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00537394 · 517 participants · Start Jan 2008 · Primary completion May 2012
Drug: Enfuvirtide; Raltegravir and 4 more · For: HIV Infections
Sites: Birmingham, Alabama; Long Beach, California; Los Angeles, California · 64 sites in all
- An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).Pivotal-lookingCompleted
Tibotec Pharmaceuticals, IrelandIndustry
NCT00359021 · 503 participants · Start Jun 2006 · Primary completion Jan 2012
Drug: TMC125 · For: HIV-1
Sites: Phoenix, Arizona; Little Rock, Arkansas; Beverly Hills, California · 72 sites in all
- Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected AdultsPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT02605954 · 275 participants · Start Nov 18, 2015 · Primary completion Jun 14, 2017
Drug: E/C/F/TAF; ABC/3TC and 1 more · For: HIV-1 Infection
Sites: Phoenix, Arizona; Los Angeles, California; Washington D.C., District of Columbia · 49 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pain286
- drug interaction282
- drug resistance266
- anxiety247
- emotional distress243
- virologic failure237
- anhedonia219
- death208
- treatment failure203
- chronic kidney disease192
- lipodystrophy acquired175
- foetal exposure during pregnancy166
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 59 |
| 2008 | 153 |
| 2009 | 255 |
| 2010 | 257 |
| 2011 | 196 |
| 2012 | 278 |
| 2013 | 265 |
| 2014 | 257 |
| 2015 | 375 |
| 2016 | 343 |
| 2017 | 267 |
| 2018 | 250 |
| 2019 | 317 |
| 2020 | 369 |
| 2021 | 222 |
| 2022 | 231 |
| 2023 | 158 |
| 2024 | 93 |
| 2025 | 45 |
| 2026 | 48 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
To Be Discontinued · updated Apr 28, 2026
Etravirine, Tablet, 100 mg (NDC 10147-0570-1). Discontinuation of the manufacture of the drug
To Be Discontinued · updated Apr 28, 2026
Intelence, Tablet, 100 mg (NDC 59676-570-01). Discontinuation of the manufacture of the drug
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Intelence (Etravirine)
2024 spending
$2.5M
Beneficiaries
281
1,596 claims
Per beneficiary
$8,809
$22.63 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $68,238,317 |
| 2021 | $46,936,731 |
| 2022 | $12,895,562 |
| 2023 | $4,717,541 |
| 2024 | $2,475,203 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Switch to etravirine for HIV-positive patients receiving statin treatment: a prospective study.
Ciaffi L, Cavassini M, Genne D, et al. · Eur J Clin Invest 2015 · Clinical Trial, Phase III, Multicenter Study
- The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects.
Ruane PJ, Brinson C, Ramgopal M, et al. · HIV Med 2015 · Clinical Trial, Multicenter Study
- Effects of etravirine versus placebo on health-related quality of life in treatment-experienced HIV patients as measured by the functional assessment of human immunodeficiency virus infection (FAHI) questionnaire in the DUET trials.
Cella D, Gilet H, Viala-Danten M, et al. · HIV Clin Trials 2010 · Clinical Trial, Phase III, Multicenter Study
- Therapeutic drug monitoring in treatment-experienced HIV-infected patients receiving darunavir-based salvage regimens: A case series.
Landry S, Chen CN, Patel N, et al. · Antiviral Res 2018 · Clinical Trial, Research Support, Non-U.S. Gov't
- Improved prediction of salvage antiretroviral therapy outcomes using ultrasensitive HIV-1 drug resistance testing.
Pou C, Noguera-Julian M, Pérez-Álvarez S, et al. · Clin Infect Dis 2014 · Clinical Trial, Multicenter Study
- Interactions of Antiretroviral Drugs with Food, Beverages, Dietary Supplements, and Alcohol: A Systematic Review and Meta-analyses.
Wiesner A, Skroska M, Gawlik G, et al. · AIDS Behav 2023 · Meta-Analysis, Systematic Review
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.